Celgene, the manufacturer of Revlimid (lenalidomide), announced today positive results from a Phase 3 clinical trial using Revlimid as first-line therapy for newly diagnosed multiple myeloma patients. Results show that Revlimid in combination with melphalan (Alkeran) and prednisone, followed by continuous Revlimid, significantly improved time to tumor progression.

Check back for further coverage on The Myeloma Beacon.

Update: Please see The Myeloma Beacon's full coverage of Revlimid as a first-line therapy for myeloma.